From 13 till 17 June 2023: HIGHLIGHTS ON MALIGNANT LYMPHOMA
Your direct line with Lugano
From 13 till 17 June 2023, the International Conference on Malignant Lymphoma (ICML) is – as usually – taking place in Lugano, Switzerland. The MediMix team is onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen.
And, we also dive into posters and hot topics with both Belgian and international experts.
Stay tuned!
With the educational support of:
Daily highlights
Dr. Willem Daneels provides valuable insights on the management of aggressive lymphomas. He presents the outcomes of a non-inferiority trial comparing observation versus radiotherapy in patients with primary mediastinal b-cell
Prof. Marc André discusses the outcomes of the fil-rouge trial comparing frontline intensified ABVD with PET-adapted ABVD in advanced Hodgkin lymphoma. Prof. André also presents results of the SWOG S1826
Prof. Ann Janssens from UZ Leuven shares a summary on the informative session on CLL and Richter syndrome.
In-depth stories
Dr Jason Westin, hematologist at Texas MD Anderson Cancer Center, Houston gives insight into the overall survival findings from the ZUMA-7 trial of axicabtagene ciloleucel in patients with relapsed or
Prof. Stephan Stilgenbauer, hematologist at the Ulm University in Germany shares his view on the role of BTK-inhibitors in B-cell malignancies. He discusses the potential of second-generation BTK-inhibitors and provides
Prof. Ann Janssens, hematologist at UZ Leuven, discusses the outcomes of the SELENE study for which she was one of the investigators. This phase 3 study evaluated ibrutinib plus bendamustine-rituximab
Poster selection
Dr. Gustav Cederquist from the Memorial Sloan Kettering Cancer Center, New Yorkevaluated the potential of brain radiotherapy as an effective bridge for chemo-refractory or progressive secondary CNS lymphoma.
Central nervous system (CNS) relapse in diffuse large B-cell lymphoma is associated with poor outcomes necessitating the identification of high-risk patients. To refine CNS risk stratification, a better understanding of
Enteropathy associated T-cell lymphoma is a rare peripheral T-cell lymphoma with a poor prognosis. Dr. Frederik Meeuwes, hematologist from the Treant hospital in Emmen presented a population-based cohort study on
Vera De Jonge, PhD student from the VUMC, Amsterdam and Joanna Bult, PhD student from the University Medical Center Groningen assessed the impact of a rearrangement of the MYC oncogene